PE20220381A1 - Formulacion de tableta vaginal - Google Patents

Formulacion de tableta vaginal

Info

Publication number
PE20220381A1
PE20220381A1 PE2021001545A PE2021001545A PE20220381A1 PE 20220381 A1 PE20220381 A1 PE 20220381A1 PE 2021001545 A PE2021001545 A PE 2021001545A PE 2021001545 A PE2021001545 A PE 2021001545A PE 20220381 A1 PE20220381 A1 PE 20220381A1
Authority
PE
Peru
Prior art keywords
tablet formulation
vaginal tablet
vaginal
gdl
hypromellose
Prior art date
Application number
PE2021001545A
Other languages
English (en)
Inventor
Ulf Ellervik
Sophie Manner
Olov Sterner
Helena Strevens
Nils-Olof Lindberg
Annette Safholm
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of PE20220381A1 publication Critical patent/PE20220381A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica solida que comprende de 5 a 30% p/p de glucono delta-lactona (GDL) y de 10 a 40% p/p de e hipromelosa (HPMC), la cual es adecuada para administracion vaginal y para el tratamiento de infecciones microbianas vaginales
PE2021001545A 2019-04-05 2020-04-03 Formulacion de tableta vaginal PE20220381A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19167495 2019-04-05
PCT/EP2020/059582 WO2020201515A1 (en) 2019-04-05 2020-04-03 Vaginal tablet formulation

Publications (1)

Publication Number Publication Date
PE20220381A1 true PE20220381A1 (es) 2022-03-18

Family

ID=66101895

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001545A PE20220381A1 (es) 2019-04-05 2020-04-03 Formulacion de tableta vaginal

Country Status (24)

Country Link
US (1) US20220193031A1 (es)
EP (1) EP3976000B1 (es)
JP (1) JP2022537478A (es)
KR (1) KR20210148195A (es)
CN (1) CN113660928B (es)
AR (1) AR118580A1 (es)
AU (1) AU2020252268A1 (es)
BR (1) BR112021019999A2 (es)
CA (1) CA3134086A1 (es)
CL (1) CL2021002430A1 (es)
CO (1) CO2021014253A2 (es)
EA (1) EA202192716A1 (es)
ES (1) ES2961736T3 (es)
HU (1) HUE062772T2 (es)
IL (1) IL286942A (es)
MA (1) MA56011A (es)
MX (1) MX2021012146A (es)
PE (1) PE20220381A1 (es)
PL (1) PL3976000T3 (es)
SG (1) SG11202110236QA (es)
TW (1) TW202103693A (es)
UA (1) UA127823C2 (es)
WO (1) WO2020201515A1 (es)
ZA (1) ZA202106877B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0956858B1 (en) * 1998-04-30 2001-10-31 Renata Maria Anna Cavaliere Vesely Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for treatment of vaginal infections
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
HUE056303T2 (hu) 2016-04-06 2022-02-28 Gedea Biotech Ab Glükono-delta-lakton hüvelyi gombás fertõzések kezelésére
KR102650182B1 (ko) 2017-10-06 2024-03-21 게데아 바이오테크 아베 미생물 감염의 치료 및/또는 예방에서 사용하기 위한 글루콘산 유도체

Also Published As

Publication number Publication date
UA127823C2 (uk) 2024-01-10
ZA202106877B (en) 2023-03-29
EA202192716A1 (ru) 2022-01-17
CL2021002430A1 (es) 2022-07-01
HUE062772T2 (hu) 2023-12-28
AR118580A1 (es) 2021-10-20
EP3976000C0 (en) 2023-08-02
SG11202110236QA (en) 2021-10-28
BR112021019999A2 (pt) 2021-12-07
TW202103693A (zh) 2021-02-01
CA3134086A1 (en) 2020-10-08
JP2022537478A (ja) 2022-08-26
MX2021012146A (es) 2021-12-10
EP3976000B1 (en) 2023-08-02
ES2961736T3 (es) 2024-03-13
CO2021014253A2 (es) 2021-11-19
PL3976000T3 (pl) 2023-12-04
IL286942A (en) 2021-12-01
CN113660928B (zh) 2024-04-05
KR20210148195A (ko) 2021-12-07
WO2020201515A1 (en) 2020-10-08
EP3976000A1 (en) 2022-04-06
CN113660928A (zh) 2021-11-16
MA56011A (fr) 2022-04-06
US20220193031A1 (en) 2022-06-23
AU2020252268A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
CY1109910T1 (el) Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
AR107391A1 (es) Formulaciones / composiciones que comprenden un inhibidor de btk
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
CO6640318A2 (es) Formas de dosificación oral de bendamustina
MX2020000009A (es) Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos.
PE20220381A1 (es) Formulacion de tableta vaginal
BR112022014772A2 (pt) Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas
CL2018002705A1 (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
BR112018008835A2 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
CY1113544T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
BR112021026471A2 (pt) Formulações de dose sólida para a liberação sem agulha
BR112021024054A2 (pt) Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos.
ES2280150T1 (es) Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma.
AR117298A1 (es) Aglutinante de péptido
CL2023000110A1 (es) Composición farmacéutica acuosa que comprende un antagonista del receptor p2y12
AR123553A1 (es) Formas farmacéuticas sólidas con perfiles de disgregación mejorados
WO2022146355A3 (en) Pharmaceutical capsule compositions of alogliptine
UA130320U (uk) Фармацевтична композиція для перорального застосування для лікування інфекційних захворювань
UA109243U (uk) Тверда лікарська форма, що містить інгібітор віл протеази